Therapeutic intervention and signaling.

[1]  L. Peso,et al.  Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. , 1997, Science.

[2]  B. Hemmings.  Update: PtdIns(3,4,5)P3 Gets Its Message Across , 1997, Science.

[3]  F. McCormick,et al.  Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. , 1997, Science.

[4]  G. Panayotou,et al.  Phosphoinositide 3-kinases: a conserved family of signal transducers. , 1997, Trends in biochemical sciences.

[5]  Monia Bp.  First- and second-generation antisense inhibitors targeted to human c-raf kinase: in vitro and in vivo studies. , 1997 .

[6]  P. Casey,et al.  Farnesyltransferase Inhibitors Alter the Prenylation and Growth-stimulating Function of RhoB* , 1997, The Journal of Biological Chemistry.

[7]  Guido Kroemer,et al.  The proto-oncogene Bcl-2 and its role in regulating apoptosis , 1997, Nature Medicine.

[8]  M. Lewis,et al.  Direct Demonstration of Geranylgeranylation and Farnesylation of Ki-Ras in Vivo * , 1997, The Journal of Biological Chemistry.

[9]  A. Ganser,et al.  Specific Hammerhead Ribozyme-mediated Cleavage of Mutant N-ras mRNA in Vitro and ex Vivo , 1997, The Journal of Biological Chemistry.

[10]  W. R. Bishop,et al.  K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors* , 1997, The Journal of Biological Chemistry.

[11]  P. Warne,et al.  Role of Phosphoinositide 3-OH Kinase in Cell Transformation and Control of the Actin Cytoskeleton by Ras , 1997, Cell.

[12]  C. Der,et al.  The Ras-related Protein Rheb Is Farnesylated and Antagonizes Ras Signaling and Transformation* , 1997, The Journal of Biological Chemistry.

[13]  W. R. Bishop,et al.  Characterization of Ha-Ras, N-Ras, Ki-Ras4A, and Ki-Ras4B as in Vitro Substrates for Farnesyl Protein Transferase and Geranylgeranyl Protein Transferase Type I* , 1997, The Journal of Biological Chemistry.

[14]  P. Cohen,et al.  Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα , 1997, Current Biology.

[15]  J. Rine,et al.  Modulation of Ras and a-Factor Function by Carboxyl-Terminal Proteolysis , 1997, Science.

[16]  P. Casey,et al.  Crystal Structure of Protein Farnesyltransferase at 2.25 Angstrom Resolution , 1997, Science.

[17]  J. Zweier,et al.  Mitogenic Signaling Mediated by Oxidants in Ras-Transformed Fibroblasts , 1997, Science.

[18]  M. Kawada,et al.  Inhibition of anchorage-independent growth of ras-transformed cells on polyHEMA surface by antisense oligodeoxynucleotides directed against K-ras. , 1997, Biochemical and biophysical research communications.

[19]  Lewis C Cantley,et al.  PI3K: Downstream AKTion Blocks Apoptosis , 1997, Cell.

[20]  David R. Kaplan,et al.  Direct Regulation of the Akt Proto-Oncogene Product by Phosphatidylinositol-3,4-bisphosphate , 1997, Science.

[21]  David R. Kaplan,et al.  Regulation of Neuronal Survival by the Serine-Threonine Protein Kinase Akt , 1997, Science.

[22]  E. Querfurth,et al.  Distinct specificity in the recognition of phosphoinositides by the pleckstrin homology domains of dynamin and Bruton's tyrosine kinase. , 1996, The EMBO journal.

[23]  M. Wigler,et al.  Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation , 1996, Molecular and cellular biology.

[24]  Doriano Fabbro,et al.  Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase , 1996, Nature Medicine.

[25]  F. McCormick,et al.  A role for Rho in Ras transformation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[26]  B. Burgering,et al.  Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction , 1995, Nature.

[27]  A. Kral,et al.  Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice , 1995, Nature Medicine.

[28]  F. McCormick,et al.  An essential role for Rac in Ras transformation , 1995, Nature.

[29]  J. Goldstein,et al.  Polylysine and CVIM Sequences of K-RasB Dictate Specificity of Prenylation and Confer Resistance to Benzodiazepine Peptidomimetic in Vitro(*) , 1995, The Journal of Biological Chemistry.

[30]  M. Wigler,et al.  Multiple ras functions can contribute to mammalian cell transformation , 1995, Cell.

[31]  Michael J. Fry,et al.  Phosphatidylinositol-3-OH kinase direct target of Ras , 1994, Nature.

[32]  N. Kohl,et al.  Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic , 1994, Cell.

[33]  A. Levinson,et al.  Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. , 1993, Science.

[34]  R L Smith,et al.  Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. , 1993, Science.

[35]  C. Der,et al.  Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[36]  C. Der,et al.  Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein , 1992, Molecular and cellular biology.

[37]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[38]  D. Lowy,et al.  Function and regulation of ras. , 1993, Annual review of biochemistry.

[39]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .